397246-12-7

Basic information

• Product Name: (R)-2-TERT-BUTYLOXYCARBONYLAMINO-PENTANE-1,5-DIOL
• Synonyms: BOC-R-GLU-OL2;(R)-2-TERT-BUTYLOXYCARBONYLAMINO-PENTANE-1,5-DIOL;Carbamic acid, [(1R)-4-hydroxy-1-(hydroxymethyl)butyl]-, 1,1-dimethylethyl
• CAS NO: 397246-12-7
• Molecular Formula: C10H21NO4
• Molecular Weight: 219.28
• Product Categories: N-BOC
• Mol File: 397246-12-7.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-2-TERT-BUTYLOXYCARBONYLAMINO-PENTANE-1,5-DIOL(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-2-TERT-BUTYLOXYCARBONYLAMINO-PENTANE-1,5-DIOL(397246-12-7)
• EPA Substance Registry System: (R)-2-TERT-BUTYLOXYCARBONYLAMINO-PENTANE-1,5-DIOL(397246-12-7)

Safety Data

• Hazardous Substances Data: 397246-12-7(Hazardous Substances Data)

Usage

General Description

The chemical compound (R)-2-TERT-BUTYLOXYCARBONYLAMINO-PENTANE-1,5-DIOL, also known as Fmoc-L-lysine-OH, is an amino acid derivative commonly used in organic synthesis and peptide chemistry. It is the protected form of L-lysine, with the Fmoc (9-fluorenylmethyloxycarbonyl) group serving as a protecting group for the amine functional group. (R)-2-TERT-BUTYLOXYCARBONYLAMINO-PENTANE-1,5-DIOL is often utilized as a building block for the synthesis of peptides and peptidomimetics, as well as in the preparation of various natural products and pharmaceuticals. Additionally, it is commonly employed as a reagent in solid-phase peptide synthesis due to its stability and ease of synthesis.

Upstream product

• 861658-15-3 1,5-dimethyl (2R)-2-[[(tert-butoxy)carbonyl]amino]pentanedioate 
• 861658-15-3 1,5-dimethyl 2-[(t-butoxycarbonyl)amino]pentanedioate 
• 617-65-2 Glutamic acid 
• 6525-53-7 glutamic acid dimethyl ether 
• 34404-28-9 N-[(1,1-dimethylethoxy)carbonyl]-D-glutamic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 56-86-0 L-glutamic acid 
• 23150-65-4 L-glutamic dimethyl ester hydrochloride 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 6525-53-7 L-glutamic acid dimethyl ester 
• 98-79-3 L-Pyroglutamic acid 
• 4931-66-2 methyl (S)-pyroglutamate 
• 108963-96-8 (S)-1-tert-butoxycarbonyl-5-methoxycarbonyl-pyrrolidin-2-one 
• 130696-54-7 diethyl (tert-butoxycarbonyl)-L-glutamate 

Downstream Products

• 1295568-51-2 (S)-N-(tetrahydro-2H-pyran-3-yl)cinnamamide 
• 125982-23-2 ⁽⁵⁾-tert-butyl (6-oxotetrahydro-2H-pyran-3-yl)carbamate 
• 71974-09-9 γ-D-Glutamyl-L-meso-diaminopimelic acid dipeptide 
• 1607592-28-8 [(5S)-5-aminotetrahydro-2H-pyran-2-yl]acetonitrile hydrochloride 
• 334618-23-4 3-(R)-aminopiperidine dihydrochloride 
• 454713-13-4 tert-butyl (R)-(+)-(N-benzylpiperidin-3-yl)carbamate 
• 121706-11-4 (-)-n-Hexyl indolactam V 
• 478828-62-5 (1-benzylpiperidin-3-yl)carbamic acid tert-butyl ester 
• 1295722-66-5 (S)-tert-butyl (tetrahydro-2H-pyran-3-yl)carbamate 
• 1157849-50-7 C₆H₁₄N₂*(x)ClH 
• 84590-48-7 indolactam V 

Relevant articles and documents

Synthetic process of anti-hyperglycemic drug intermediate R-3-amino-piperidine dihydrochloride

The invention relates to a synthetic process of an anti-hyperglycemic drug intermediate R-3-amino-piperidine dihydrochloride. The synthetic process comprises the steps: using inexpensive L-glutamic acid as a starting material, and performing esterification, amino protection, reduction, hydroxyl protection, substitution, cyclization and removal of protecting groups for amino groups so as to obtainthe R-3-amino-piperidine dihydrochloride. Compared with the prior art, the synthetic process has cheap and easily available raw materials, good selectivity, good atomic economy, high total yield and mild reaction conditions, and is suitable for industrial production.

CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF

The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or mediated, at least in part, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is generally applicable to compounds which inhibit myofibroblast differentiation.

(R) - 3-amino-piperidine dihydrochloride preparation method

The invention discloses a method for preparing (R)-3-amino piperidine hydrochloride. D-glutamic acid is taken as a starting material, and the (R)-3-amino piperidine hydrochloride is obtained by reaction in the following five steps: (1) hydroxyl esterification and amido Boc protection; (2) ester reduction; (3) hydroxyl activation; (4) cyclization; (5) amino Boc removal protection. The preparation method disclosed by the invention is short in synthetic route and low in cost, and industrial production can be achieved.